Kornimate/medical-research-clean huggingface dataset:
functional role of runx1 mutations in the etiology of acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to elucidate the role of runx1 in acute myeloid leukemia (aml), in particular, the transcriptional regulation of genes by mutated forms of this protein. this research will study the effect of mutations found in aml patients

the runx1 gene, located at chromosomal band 21q22, is a transcription factor, crucial for hematopoiesis and the generation of hematopoietic stem cells in the embryo. runx1 is the most frequent target for chromosomal translocation in leukemia. in addition, point mutations in the runx1 gene have been found to constitute an important mode of genetic alteration in development of leukemia. recent publications stressing the clinical need for implementing runx1 point mutations as both a diagnostic and unfavorable prognostic marker of aml, have aroused particular interest in the functional role of runx1 in this disease. in order to pinpoint specific runx1 target genes involved in pre-leukemic transformation or exacerbation of existing leukemia, the investigators plan to compare expression profiles from human hematopoietic progenitors overexpressing a mutated form of runx1with controls (runx1 wild-type and knocked-down). in this study the investigators intend to collect blood, after receiving informed consent, from umbilical cords of neonates born vaginally, in order to isolate cd34+ hematopoietic progenitors. human umbilical cord blood contains relatively high numbers of cd34+ cells, which may be frozen directly after collection and used as a source of progenitor cells for further culture or direct analysis.

Eligibility criteria:
inclusion criteria: * consenting women who have had full-term birth exclusion criteria: * systemic disease
identification of genetic causes of bicuspid aortic valve disease

Conditions: Bicuspid Aortic Valve

Summary: bavgenetics is a partnership between investigators at boston university, brigham and women's hospital, and massachusetts general hospital dedicated to discovering the genetic causes of bicuspid aortic valve disease and associated aortic disease.

the investigators at bavgenetics are dedicated to discovering the mechanisms of bicuspid aortic valve disease and why individual genetics seem to play such an important role in generation of this disease. if you have, or have had, a bicuspid aortic valve, we seek your help in this effort by volunteering to donate dna to the bav registry, so that this disease can be better understood and therapies for it can be developed. the bav registry is comprised of patients who have donated dna collected from saliva (spit) and have provided us with personal health information that tells us about their bicuspid aortic valve. individuals in the registry have signed the consent form, filled out the medical history questionnaire and the authorization form, and provided dna via our saliva sample kits. we will send you the requisite forms so that you receive the most up-to-date information about the study as older forms may be outdated. we also need paper copies of the forms; therefore, we send all the forms via ground mail along with a pre-paid return envelope for your convenience.

Eligibility criteria:
inclusion criteria: * any adult patient ≥ 14 years of age may be recruited regardless of gender, ethnicity or racial group. * patients with a diagnosis of bicuspid aortic valve will be enrolled. * patients who have had their bicuspid aortic valve previously replaced will also be enrolled. * relatives of patients with a diagnosis of bicuspid aortic valve are also welcomed to be enrolled regardless if they have bav or not, as it is helpful to examine the dna of first degree relatives. exclusion criteria: * non-english speaking

Keywords: bicuspid aortic valve
nice guideline 'red flags' to predict serious outcome after transient loss of consciousness

Conditions: Syncope

Summary: this study is designed to evaluate the accuracy of the national institute for health and clinical excellence (nice) guideline 'red flags' to identify patients at high risk of short term serious outcome when presenting in the emergency department (ed) with transient loss of consciousness (tloc). red flags were defined as ecg abnormality, history or physical signs of heart failure, tloc during exercise, family history of sudden cardiac death at an age \ 65 years.


Eligibility criteria:
inclusion criteria: * adult patients (\>= 16 years) with a complaint of tloc exclusion criteria: * patients needing immediate treatment, with trauma related or drug or alcohol related tloc were excluded, as well as patient with persistent altered level of consciousness, simple fall and drop attack
a study of pemetrexed and cyclophosphamide given every 21 days in advanced breast cancer patients

Conditions: Breast Cancer

Summary: this is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer. a single arm phase 1 dose finding (establish maximum tolerated dose) study precedes the randomized phase 2 portion.


Eligibility criteria:
inclusion criteria: - you must be female and at least 18 years old. - you must have been diagnosed with breast cancer. - your pre-study lab tests are within study requirements. - you must be willing to take folic acid and vitamin b12. exclusion criteria: - you are pregnant or breastfeeding. - you have another illness that your doctor thinks would make you unable to participate. - you are currently taking aspirin or aspirin-like medicine and are unable to stop for a few days during each cycle of therapy.

Keywords: advanced breast cancer
jiu-wei-zhen-xiao granule for advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this is a piolt single-arm trial of jiu-wei-zhen-xiao granule, extracted from nine kinds of chinese medicnie, for the treatment in patients with advanced, unresectable hepatocellular carcinoma(hcc). the primary objective is to assess its therapeutic efficacy in patients with unresectable hcc. the primary endpoint is overall survival (os) after the use of 12-week drug. secondary endpoints include progression-free survival (pfs) after the use of 12-week drug, the improvement of the score of the european organization for reasearch and treatment of cancer quality of life questionnaire c30 (eortc qlq-c30), the changes of the liver function, coagulation function, the size of solid tumors,"du-tan-yu-jie zheng" in chinese medicine, pain visual analogue scale and toxicity profile of jiu-wei-zhen-xiao granule.


Eligibility criteria:
inclusion criteria: 1. age:18\~75 years; 2. patients must have diagnosis of advanced hepatocellular cancer (hcc) by one of the following: (1) histopathology; (2) elevated serum alpha-fetoprotein (afp) \>400 ng/ml and findings on magnetic resonance imaging (mri) or computed tomography (ct) scans characteristic of hcc; (3) findings on triple phase mri or ct scans characteristic of hcc in patients with cirrhosis and tumors at least 1 cm or greater, without a curative treatment option (transplant, resection, or ablation). 3.the clinical staging of hcc is b or c or d staging as the barceln clinical liver cancer classification(bclc); 4. patients with hepatitis b virus infection; 5. patients with "du-tan-yu-jie zheng" in chinese medicine; 6. karnofsky score ≥60; 7. ability to understand and willingness to sign a written informed consent document. exclusion criteria: 1. patients with unstable vital signs; 2. any uncontrolled, severe, intercurrent illness including but not limited to ongoing or active infection, heart, brain, lung and other systemic diseases or other kinds of tumors; 3. known history of allergy to the ingredients of this product; 4. is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of trial treatment; 5. receipt of any other investigational agents ≤ 1 month of the first dose of study treatment; 6. patients who cannot take oral medication.
surfactant administration by insure or thin catheter

Conditions: RDS of Prematurity; Surfactant Deficiency Syndrome Neonatal; Analgesia

Summary: this trial evaluates the efficacy and safety of surfactant administration with thin catheter technique together with analgesic premedication in comparison with the established insure-strategy. it will provide valuable knowledge to improve clinical methodology and enhance lung protective treatment strategies for preterm infants.

to compare two approaches for surfactant administration during cpap in preterm infants, the insure and the lisa technique, using premedication intubation protocols, and investigate aspects of safety, stress and pain, timely administration of the drug, response in oxygenation and pulmonary outcome. our study asks whether (p) among infants born \<32 weeks' gestation with rds (i) does surfactant administration with lisa and analgesia premedication (c) versus surfactant administration according to the insure protocol (o) improve oxygenation and reduce the rate of respiratory failure and need for intubation and mechanical ventilation (t) within 48 hours of the procedure primary outcomes: 1. positive effect: oxygenation measured as arterial to alveolar ratio (a/a ratio) at 24 hours post-procedure. 2. negative effect: need for mechanical ventilation (mv) within 48 hours post-procedure. safety outcomes: 1. time from meeting the fio2 or a/a ratio criteria for surfactant treatment until surfactant administration 2. number of tries before successful intubation/placement of catheter 3. positive pressure ventilation during the procedure - yes/no/duration (minutes) 4. stress and pain (changes in heart rate, blood pressure and biip-scale)

Eligibility criteria:
inclusion criteria: * infants born before 32 completed weeks of gestation on cpap, with clinical and radiological signs of rds and need for surfactant treatment. exclusion criteria: * infants requiring surfactant as part of delivery room resuscitation are not eligible. infants will be excluded from the final analysis if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation, including: congenital diaphragmatic hernia; tracheo-oesophageal fistula or cyanotic heart disease.

Keywords: lisa (less invasive surfactant administration) insure cpap
improving quality of life using patient reported outcomes measures post-operative via text messaging

Conditions: Gynecologic Cancer

Summary: this study is investigating a new way to monitor patients who are recovering at home after surgery. this study uses text messages to ask patients to review their own symptoms and then reply with the level of severity of specific symptoms. based on each patient's specific response to the text message survey, a pre-programmed, automated response will be sent from the study prompting the patient to take specific actions (or no action if no symptoms). investigators will assess whether this method improves patients' well-being as compared to the current standard of care for patients. currently, after surgery, patients are provided counseling and written instructions when they leave the hospital on how to care for themselves at home. if the patient has questions or concerns, they contact their care team. the optimal way to help patients assess their own symptoms at home remains unknown. investigators are also assessing if using the symptom survey reduces readmissions to the hospital.


Eligibility criteria:
inclusion criteria: * age 18 years of age or greater. * planning to undergo a surgical procedure via a laparotomy incision for a suspected or known gynecologic malignancy. there is no restriction on the spectrum of pathology or disease. * the ability and willingness to send and receive short messaging service (sms) text messages. * able to read and understand english. * willing and able to provide informed consent exclusion criteria: * persons who are planning to undergo a minimally invasive procedure without laparotomy. * persons unable to be contacted by sms text message or choose to opt-out of the study. * patients who do not have access to the internet via a home computer or a smart phone.

Keywords: laparotomy
advanced diffusion tensor mri for breast cancer

Conditions: Breast Cancer; Breast Diseases

Summary: the purpose of this research is to evaluate the accuracy of the bit-motion (breast imaging tensor-motion) software with non-contrast mri scanning to detect breast cancer.

the goal of this study is to answer the question: what is the ability of the bit-motion (breast imaging tensor-motion) software to detect and discriminate between benign and malignant breast lesions that are identified on mammogram (mg) and ultrasound (us) examinations. women over the age of 18 who have a breast lesion that is seen on mg or us will be eligible to enroll. participation in this study will involve one non-invasive non-contrast mri scan of the breasts.

Eligibility criteria:
inclusion criteria: * female * scheduled for ultrasound or stereotactic guided breast biopsy * \> 18 years of age * able to tolerate up to 90 minutes in the mri scanner exclusion criteria: * male * has a medical condition that, in the opinion of the investigator, puts the subject at significant risk * has any contraindication to the mri examination as determined by standard northshore university health system relative to mri safety * cannot comprehend or complete the informed consent form

Keywords: diffusion tensor imaging mri
assessment of novel sound changing principles in hearing instruments to determine their application - 2018_16

Conditions: Hearing Loss; Normal Hearing

Summary: an eeg study using continuous speech stimuli to assess neural language processing in a hearing impaired population. participants listen to short radio excerpts in different signal to noise ratios (snr) and answer comprehension questions as well as listening effort questions. we assess the effect of different algorithms on neural language processing as well as subjective listening effort. each participant hears 12 randomized segments of speech (about 4min long each) with different settings on their hearing aid (reference condition, noise reduction algorithm, beam forming algorithm). this will be a controlled, single blinded and randomized active comparator clinical evaluation which will be conducted mono centric at sonova ag headquarter based in stäfa.


Eligibility criteria:
inclusion criteria: * healthy outer ear (without previous surgical procedures) * ability to fill in a questionnaire conscientiously * informed consent as documented by signature exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product * limited mobility and not in the position to attend weekly appointments * limited ability to describe listening impressions/experiences and the use of the hearing aid * inability to produce a reliable hearing test result * massively limited dexterity * known psychological problems * known central hearing disorders
rhythm control versus rate control for new onset atrial fibrillation

Conditions: Atrial Fibrillation New Onset; Atrial Fibrillation Paroxysmal

Summary: adult patients who are diagnosed new onset atrial fibrillation with rapid ventricular response within 7 days after non-cardiac non-thoracic surgery are enrolled.

after randomization, they are allocated to rhythm control strategy group or rate control strategy group. in rhythm control strategy group, patients are given amiodarone primarily for the purpose of sinus conversion of cardiac rhythm. in rate control strategy group, patients are given diltiazem or esmolol for the purpose of rate control. the rate of sinus conversion within 48 hours after treatment are compared.

Eligibility criteria:
inclusion criteria: * older than 18 years * newly diagnosed atrial fibrillation or flutter * patients with atrial fibrillation or flutter that occurred within 7 days after non-cardiac non-thoracic surgery * atrial fibrillation or flutter with rapid ventricular response(hr ≥110/min) * patients without hemodynamic instability (mbp≥65mmhg with norepinephrine continuous infusion less than 5mcg/min or without vasopressor support) exclusion criteria: * atrial fibrillation or flutter prolonged more than 48 hours without anticoagulation * patients who have decreased cardiac function or heart failure (ef \<40%) * patients who have cardiac conduction disorder, qt prolongation(qtc ≥500ms)
study of the effectiveness of administration of meperidine on the length of active phase of labor in women

Conditions: Labor Pain

Summary: this study aims to evaluate the effect of meperidine on the length of active phase of labor in nulliparous or multiparous women, who will be randomized into two (control and study) groups. our hypothesis is that the use of meperidine during active labor has no effect on the duration of labor.

* our aim is to examine the effect of the opioid derivative meperidine used during labor on the duration of labor in singleton pregnancies. * the sample size was calculated using the number cruncher statistical system (ncss) / pass 2007. power 80% and significance level (α) 0.05, the mean (mean) ± standard deviation (sd) of the first 20 individuals included in the control group of the study (296.04 ± 170.02) and has minimal clinical significance for the active phase of labor from previous studies. we found that the sample size should be 200 (100/100) considering the duration (30 minutes). * a simple randomisation using a random-number table was performed by the independent nurse staff, who took no further part in the study.using the sealed envelope technique, parturients were randomly allocated to two groups: a meperidine group and b normal saline group * age, height, weight, body mass index (bmi), gravida, parity, week of gestation, expected fetal weight (efw), hemoglobin (hb) and hematocrit (hct) values and episiotomy requirements were recorded in two groups.gender, birth weight, 1st and 5th minute apgar scores and presence of meconium aspiration of the newborns in two groups were recorded. * during labor, oxytocin induction was not performed during the latent phase in accordance with the routine protocol of our hospital. pregnant women in both groups were given oxytocin (synpitan® amp) at a concentration of 1% by 10 drops/min by performing amniotomy when bishop score was 6 or cervix dilation was 4 cm and when 70% effacement was achieved. in the meperidine group, when the cervical opening was 6 cm and 70% washout, 25 mg iv bolus injection of meperidine (2.5 ml) was administered. the same amount (2.5 ml) of physiological saline was administered intravenously to the subjects in the control group. the patients were followed in nst until 10 cm clearance and 100% effacement. this time was recorded as active phase time. the time from the end of the active phase period to the birth of the baby was recorded as the duration of the second phase of birth. * the primary outcome of interest in this study is the duration of active phase of labor .

Eligibility criteria:
inclusion criteria: * gestational age between 38 and 42 weeks * live fetus * cephalic presentation * in active phase of labour exclusion criteria: * placenta previa, placental abruption * caesarean section or any uterine scarring * multiple gestation * fetal macrosomia (≥4000 g) * meperidine allergy * use any kind of labour induction or augmentation before on admission for delivery in our hospital

Keywords: labor, meperidine, active phase, duration of labor
validation of a treadmill walking test to discriminate neurogenic claudication from vascular claudication

Conditions: Spinal Stenosis Lumbar; Low Back Pain; Peripheral Artery Disease; Claudication

Summary: the first aim of this study was to elaborate and validate a treadmill walking test that would help discriminate between neurogenic claudication from vascular claudication. the second objective of this study is to determine if the treadmill walking test can discriminate spinal stenosis from low back pain with radiating pain in lower limb.

to date, an important challenge that clinicians hare facing in the assessment and diagnosis of intermittent claudication is that pathologies associated with vascular or neurogenic claudication can coexist in the same patient. differentiation between both origins can be difficult due to variable signs and symptoms which can be atypical. the first aim of this study was to elaborate and validate a treadmill walking test that would help discriminate between neurogenic claudication from vascular claudication. the second objective of this study is to determine if the treadmill walking test can discriminate spinal stenosis from low back pain with radiating pain in lower limb. 60 participants (20 with spinal stenosis, 20 with peripheral artery disease and 20 with non-specific low back pain) will be recruited. participants will be invited to walk on a treadmill at a speed of 1,2 mph for a maximum of five minutes for both tasks (straight walking posture and inclined walking posture). each walking task will be followed by a rest time of five minutes in sitting position. it is hypothesized that walking time difference for the occurrence of pain and for pain relief will be sensitive and specific to pathologies and help to discriminate lumbar spinal stenosis.

Eligibility criteria:
inclusion criteria: lumbar spinal stenosis (lss) group : * central stenosis * pain in at least one leg * neurological signs in the lower limbs (numbness or tingling) * weaknesses in the lower limb * pain relieved by sitting or bending the trunk peripheral artery disease (pad) group : * claudication while walking * ankle-brachial index \< 0.9 * pain relieved by rest low back pain (lbp) : * pain radiating in the lower limb * weaknesses * pain relieved by sitting exclusion criteria: * foraminal stenosis * spinal stenosis with predominant back pain * symptomatic disc herniation * previous lumbar surgery * previous vascular surgery * type 1 diabetes * knee or hip osteoarthritis * hip or knee arthroplasty * inability to provide free and informed consent

Keywords: walking capacity walking posture diagnostic test